His scientific interests lie mostly in Internal medicine, Breast cancer, Surgery, Oncology and Cancer. Roger A'Hern works in the field of Internal medicine, focusing on Chemotherapy in particular. His studies in Breast cancer integrate themes in fields like Radiation dose and Computer tomographic.
His Surgery study combines topics in areas such as Multivariate analysis, Radiology and Sarcoma. In his work, Germline mutation is strongly intertwined with Immunology, which is a subfield of Oncology. His research investigates the connection between Cancer and topics such as Clinical trial that intersect with problems in Neuropathic pain, Anesthesia, Dermatology, Lidocaine and Systematic review.
His main research concerns Internal medicine, Surgery, Breast cancer, Oncology and Chemotherapy. His Internal medicine study incorporates themes from Gastroenterology, Endocrinology and Pathology. His study looks at the relationship between Surgery and fields such as Carcinoma, as well as how they intersect with chemical problems.
As a member of one scientific family, Roger A'Hern mostly works in the field of Breast cancer, focusing on Cancer research and, on occasion, Apoptosis. Roger A'Hern has researched Oncology in several fields, including Neutropenia, Clinical endpoint, Ovarian cancer, Disease and Survival analysis. The various areas that Roger A'Hern examines in his Cancer study include Relative risk and Gynecology.
His primary areas of study are Internal medicine, Breast cancer, Oncology, Cancer and Endocrinology. His Breast cancer research integrates issues from Molecular pathology and Gene expression profiling. His study in Oncology is interdisciplinary in nature, drawing from both Neoadjuvant therapy, Clinical endpoint, Clinical trial, Chemotherapy and Biomarker.
His Chemotherapy research is classified as research in Surgery. His work carried out in the field of Cancer brings together such families of science as Prospective cohort study and Pathology. His studies deal with areas such as Aromatase and Estrogen receptor, GREB1 as well as Endocrinology.
His primary areas of investigation include Internal medicine, Breast cancer, Cancer, Oncology and Prostate cancer. Roger A'Hern studied Internal medicine and Endocrinology that intersect with Letrozole. His study focuses on the intersection of Breast cancer and fields such as Molecular pathology with connections in the field of Gene expression profiling, Bioinformatics, Univariate analysis, Estrogen receptor and Chemotherapy.
His Cancer study deals with Gynecology intersecting with Residual risk, Biomarker, Clinical trial, Clinical research and Hormone therapy. His Oncology study combines topics from a wide range of disciplines, such as Germline mutation, Ovarian cancer and Immunology. The study incorporates disciplines such as Cancer research, Prostate, Cancer biomarkers and Pathology in addition to Prostate cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo;Suzanne Carreira;Shahneen Sandhu;Susana Miranda.
The New England Journal of Medicine (2015)
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett;Torsten O. Nielsen;Roger A’Hern;John Bartlett.
Journal of the National Cancer Institute (2011)
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Peter C. Fong;Timothy A. Yap;David S. Boss;Craig P. Carden.
Journal of Clinical Oncology (2010)
Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
Gerhardt Attard;Alison H.M. Reid;Roger A'Hern;Christopher Parker.
Journal of Clinical Oncology (2009)
Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
Gerhardt Attard;Joost F. Swennenhuis;David Olmos;Alison H.M. Reid.
Cancer Research (2009)
Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics
Matthew J. Ellis;Yu Tao;Jingqin Luo;Roger A'Hern.
Journal of the National Cancer Institute (2008)
Excision margins in high-risk malignant melanoma.
J. Meirion Thomas;Julia Newton-Bishop;Roger A'Hern;Gill Coombes.
The New England Journal of Medicine (2004)
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer.
T Eisen;C Boshoff;C Boshoff;I Mak;F Sapunar.
British Journal of Cancer (2000)
Analgesic Therapy in Postherpetic Neuralgia: A Quantitative Systematic Review
Kathleen Hempenstall;Turo J Nurmikko;Robert W Johnson;Roger P A'Hern.
PLOS Medicine (2005)
Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b).
Elisabeth J. Moreau;Estella Matutes;Roger P. A’Hern;Alison M. Morilla.
American Journal of Clinical Pathology (1997)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: